FIXED DOSE IN PAEDIACTRIC TRIALS FAVOURED IN EMEA WORKSHOP
June 1st, 2008
BY KEITH NUTHALL
THE USE of fixed dosing in paediatric trials has been favoured by a GlaxoSmithKline expert speaking at a European Medicines Agency (EMEA) workshop on modelling for testing child medicines.
At this London meeting, Oscar Della Pasqua, of the company's clinical pharmacology and discovery medicine department in Greenford, Middlesex, said the "use of a fixed dosing regimen results in a dynamic range of exposures" and so may be preferred initially in lieu of a dose escalation approach." This would allow for a "more complete ...
Full access to this article can be arranged with permission from the client that first ordered it. Please contact us to request access. Entries are uploaded to our archive at least one year after being published by a client – free access is restricted to International News Services journalists for background research only. The article date indicates when copy was filed to a client, not when posted to this archive. Upon client requests, International News Services will remove such articles from the archive or not upload them in the first place. They are included to demonstrate the breadth of topics undertaken by the agency and also to help promote clients’ coverage.